---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-029660"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:41:30.823277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q3 total net revenue $165.8M; BRIUMVI net sales $25.1M, net income $113.9M

## Summary
- BRIUMVI net sales $25.1M in Q3; ~$48.9M cumulative since launch; ~2,200 prescriptions from 500+ providers.
- License revenue $140.0M from Neuraxpharm upfront for ex-U.S. commercialization of BRIUMVI in RMS.
- Net income $113.9M vs net loss $35.8M YoY; cash position $229.2M as of Sept 30, 2023.
- Payor coverage for ~95% of covered lives; permanent J-Code (J2329) effective July 1, 2023.
- Company expects existing cash plus BRIUMVI revenues to fund operations into cash flow positivity.

## SEC filing metadata
- accession: 0001437749-23-029660
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/0001437749-23-029660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/tgtx20231030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-029660
- JSON: https://secwatch.observer/filing/0001437749-23-029660.json
- Plain text: https://secwatch.observer/filing/0001437749-23-029660.txt

## Key facts
- Earnings Releases
  TG THERAPEUTICS, INC. reported three and nine months ended September 30, 2023 results: revenue $165.8 million, net income $113.9 million and $27.1 million.
  - Period: three and nine months ended September 30, 2023
  - Revenue: $165.8 million
  - Net income: $113.9 million and $27.1 million
  - Result: reported results
  source text: Third quarter 2023 total net revenue of $165.8 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774923029660/0001437749-23-029660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.